High-grade serous ovarian cancer (HGSC) exhibits extensive malignant clonal diversity with widespread but non-random patterns of disease dissemination. We investigated whether local immune microenvironment factors shape tumor progression properties at the interface of tumor-infiltrating lymphocytes (TILs) and cancer cells. Through multi-region study of 212 samples from 38 patients with whole-genome sequencing, immunohistochemistry, histologic image analysis, gene expression profiling, and T and B cell receptor sequencing, we identified three immunologic subtypes across samples and extensive within-patient diversity. Epithelial CD8+ TILs negatively associated with malignant diversity, reflecting immunological pruning of tumor clones inferred by neoantigen depletion, HLA I loss of heterozygosity, and spatial tracking between T cell and tumor clones. In addition, combinatorial prognostic effects of mutational processes and immune properties were observed, illuminating how specific genomic aberration types associate with immune response and impact survival. We conclude that within-patient spatial immune microenvironment variation shapes intraperitoneal malignant spread, provoking new evolutionary perspectives on HGSC clonal dispersion.
In Brief
Integrated multi-region analysis of metastatic sites in patients with highgrade ovarian cancer highlights the connection between immune microenvironment variation and malignant spread, as well as the combinatorial prognostic value of immune and mutational features.
INTRODUCTION
High-grade serous ovarian cancer (HGSC) exhibits the highest disease mortality among gynecologic cancers. Despite recent progress with poly ADP-ribose polymerase (PARP) inhibitor-based synthetic lethal approaches exploiting homologous recombination deficiency (Mirza et al., 2016) , HGSC remains incurable in most cases. Characterized by profound genomic instability and clonal diversity, HGSC often presents with widespread peritoneal dissemination. Multi-site studies have revealed genomic intratumoral heterogeneity (ITH) as a correlate to poor survival (Schwarz et al., 2015) , as well as specific patterns of malignant cell spread within the peritoneal cavity (Bashashati et al., 2013) . Importantly, the physical distribution of malignant clones across the peritoneal cavity is non-random, with the majority of sites exhibiting clonal homogeneity and a minority of sites harboring diverse clones (McPherson et al., 2016) . This raises the hypothesis that regionspecific properties, including immunologic components of the tumor microenvironment, may modulate malignant cell invasion and expansion, thereby shaping evolutionary selection.
HGSC patients with abundant CD8+, CD4+, CD20+, and plasma cell tumor-infiltrating lymphocytes (TILs) are associated with favorable clinical outcomes (Zhang et al., 2003; Hwang et al., 2012; Nielsen et al., 2012; Kroeger et al., 2016) . TILs can respond to and temporally track neoantigens (Wick et al., 2014) and mitigate resistance to platinum chemotherapy (Wang et al., 2016) . However, much of our understanding of the immune response in HGSC derives from single biopsies; far less is known about spatial immunologic variation across distal tumor foci. Histologic imaging has revealed that lymphocyte abundance can vary between tumor foci in HGSC (Heindl et al., 2016) . Furthermore, lymphocyte expression signatures are linked to patterns of metastasis (Auer et al., 2016) . A single case report has described immunologic variation across relapse specimens (Jimé nez-Sá nchez et al., 2017); however, given the immunomodulatory effects of chemotherapy (Lo et al., 2017) , understanding of pre-treatment spatial variation is still lacking.
Beyond immunologic features, prognostic mutational processes in HGSC through analysis of point mutation, copy number, and rearrangement features has indicated a prominent association between foldback inversions (FBIs) and poor response to platinum-based chemotherapy . FBI-dominated tumors, which comprise approximately 40% of HGSC, tend to be exclusive to homologous-recombination-deficient (HRD) cases and bear a distinct pattern of high-level amplifications colocalized with foldback rearrangements typical of breakage-fusion-bridge processes (Campbell et al., 2010; . How mutational processes co-vary with immune response characteristics in HGSC remains poorly understood. This will become of central importance as clinical trials assaying synthetic lethal compounds targeting DNA repair processes combined with immune-modulation therapies read out.
We surmised that localized selective pressures imposed by immune microenvironments shape the distribution of malignant clones during disease progression. Thus, we systematically profiled the inter-relationship of clonal diversity, mutational processes, and immunologic response across a cohort of patients and multi-region samples. Genome-sequencing-based clonal decomposition, transcriptome-based T and B cell receptor sequencing, multicolor immunohistochemistry (IHC), and histologic image analyses were applied. Our results elucidate the landscape of cell-type interactions at the interface of malignant and immune cells across 212 samples from 38 patients. We show that samples robustly segregate into three distinct TIL subtypes, reflecting little or no immune infiltration, stromal infiltration, and combined epithelial and stromal infiltration. We reveal an association between these classes and malignant clone diversity properties. Regions with highest levels of epithelial immune infiltration exhibit the lowest malignant clone diversity, neoantigen depletion, and subclonal loss of heterozygosity (LOH) at human leukocyte antigen (HLA) loci as evidence of purifying selection. Moreover, T cell clonotypes, but not B cell clonotypes, spatially track with tumor clones in patients with heavily infiltrated tumors. Finally, we show combinatorial prognostic effects between mutational processes and immune infiltration with foldback inversions exhibiting high risk even in the presence of high cytotoxicity. In aggregate, our findings illuminate molecular and evolutionary properties at the immune-malignant interface in HGSC with new insights on how tumor progression and clonal dissemination are driven by immune-related selective pressures.
RESULTS

High-Resolution Multi-site Profiling of Immune and Malignant Populations in the HGSC Tumor Microenvironment
We assembled a cohort of 212 tumor samples from 38 HGSC patients ( Figure 1A and STAR Methods). Multiple samples per patient were collected via primary debulking surgery from ovary, omentum, and other distant metastatic sites (except some relapse samples from patients 7, 11, and 23; Table 1 ). TIL densities were measured by multicolor IHC, cell-type colocalization with 203 histologic images, clonotype diversity in T and B cell populations with T and B cell receptor sequencing (TCR-/BCRseq), total mRNA gene expression from the 770-gene Nanostring PanCancer Immune Profiling Panel (Cesano, 2015) augmented with 39 molecular subtyping probes (Leong et al., 2015) , mutational signatures and clonal diversity of malignant cells from whole-genome sequencing (WGS; mean depth: 863), and deep amplicon sequencing (mean depth: 16 2783, median number of loci: 188, Table S1) ( Figure S1 ). Both WGS and immune data (IHC, TCR/BCR-seq, or Nanostring) were obtained for 101 samples from 21 of 38 patients.
Tumor-Infiltrating Lymphocyte Subtypes Reveal Extensive Intrapatient Variation in Immune Responses across Peritoneal Sites
We began by profiling 188 tumor samples from 37 patients with multicolor IHC for CD8+ T cells (CD3+CD8+), CD4+ T cells (CD3+CD8-), CD20+ B cells (CD20+), and plasma cells (CD79a+CD138+). All but three patients were surveyed at multiple sites, providing an unprecedented view of intrapatient spatial variation. CD8+ T cells were the most abundant TIL type (0-1125.65 cells per high-powered field [HPF] , median: 53.08), while CD20+ B cells were the rarest (0-136.77 cells per HPF, median: 2.74). Densities of all TIL types were correlated ( Figure S2A ), with extensive variation across the cohort ( Figure S2B ).
Using TIL densities as input features, we first analyzed a discovery cohort of 119 samples from 20 patients. Hierarchical clustering revealed three major TIL subtypes: N-TIL (tumors sparsely infiltrated by TILs), S-TIL (tumors dominated by stromal TILs), and ES-TIL (tumors with substantial levels of both epithelial and stromal TILs) ( Figure 1B and Table S2 ). Based on orthogonal Nanostring probe counts, gene expression values for immuneassociated pathways, including cytotoxicity, cytokines, and T cell-and B cell-associated genes, were comparable between S-TIL and ES-TIL but lower in N-TIL ( Figure 1B ). The three TIL subtypes mapped to previously described gene expression subtypes (C1, C2, C4, and C5) of HGSC (Leong et al., 2015) (STAR Methods) . N-TIL was enriched for C4 and C5 tumors (p < 10 À5 ,
Fisher's exact test), while S-TIL was overrepresented for C1 tumors (p < 0.01, Fisher's exact test) and ES-TIL for C2 tumors, respectively (p < 10 À5 , Fisher's exact test; Figure 1B and Table   S2 ), suggesting previously reported HGSC gene expression subtypes (Tothill et al., 2008; Bell et al., 2011) largely reflect immune cell content. We analyzed IHC data from an additional cohort of 69 samples from 17 patients and observed a similar N-TIL, S-TIL, and ES-TIL distribution ( Figure 1C ), indicating reproducibility of the TIL subtypes. Among patients with R2 treatment-naive samples, 14 of 31 patients harbored only one TIL subtype: seven were N-TIL only, six were ES-TIL only, and one was S-TIL only. The remaining 17 of 31 patients harbored tumors from more than one TIL subtype ( Figure 1D ), and five patients harbored samples from all three subtypes, indicating extensive variation in immune response within patients. While the ES-TIL pattern suggests active cytolytic TIL response against tumor cells, the presence of TILs in an epithelial region does not necessarily indicate active engagement with malignant cells. We therefore used histologic image analysis to profile microscopic spatial relationships between cancer cells and TILs. For each sample, we leveraged hematoxylin and eosin (H&E) images to identify cancer cell and lymphocyte ''hotspots'' within the tumor epithelium-i.e., regions of local aggregation relative to epithelial cellular density (Figures 2A-2C and STAR Methods). We computed three measures of cancer-lymphocyte hotspot colocalization (Nawaz et al., 2015) : f C (the fraction of cancer cell hotspots that are lymphocyte hotspots); f I (the fraction of lymphocyte hotspots that are cancer cell hotspots), and f CI (fractional tissue area occupied by colocalized cancerlymphocyte hotspots) (Table S2) . ES-TIL tumors exhibited high levels of overlap between cancer and lymphocyte hotspots, while S-TIL samples contained relatively low overlap (all p < 0.05, Kruskal-Wallis test, Figures 2A and 2D) . Thus, in S-TIL tumors, the rare immune cells that enter epithelial compartments appear to fail to engage with tumor cells, possibly due to lack of recognition. Although N-TIL tumors have negligible levels of TIL, they nonetheless showed occasional immune cells that could be evaluated by hotspot analysis. Where measureable, N-TIL tumors showed similar levels of colocalization as ES-TIL ( Figure 2D) . See also Figures S1, S2, and S5 and Table S2 .
Evidence for Purifying Malignant Clonal Selection at Tumor Sites with High Epithelial Lymphocyte Infiltration
We next evaluated whether regional variation in TIL subtypes provided insight into the evolutionary trajectories and dissemination patterns of malignant clones. Using WGS on cryopreserved tissues (102 samples from 21 patients, of which 31 from 7 patients were previously described in McPherson et al., 2016) , we profiled somatic single-nucleotide variants (SNVs), allelespecific copy number, and rearrangements (Table S2) as markers of malignant clones. In addition, we performed deep (legend continued on next page) amplicon sequencing on 97 samples from 14 of these patients (66 frozen and 31 formalin-fixed samples) to calculate clonal phylogenies and the clonal composition of each sample (Figure S3 and STAR Methods) . We then related quantitative attributes of malignant clone composition to the N-TIL, S-TIL, and ES-TIL subtypes.
For each sample, we computed three continuous measures of malignant clone complexity: mixture entropy (the mixture distribution of clones present within a sample), clone divergence (the maximum phylogenetic distance between clones present within a sample; see McPherson et al., 2016) , and heterogeneity index (the mean phylogenetic distance between a randomly selected pair of clones within a sample, weighted by abundance). We also computed an orthogonal measure from WGS directly with copy-number analysis (McPherson et al., 2017b ; Table S2 and STAR Methods). All four measures of ITH were correlated (all p < 0.1, significance of Spearman r; Figure S4A ). For quality control, we confirmed entropy, clone divergence, and heterogeneity index were not correlated with tumor purity (all p > 0.2; Figure S4B ). We evaluated the associations between measures of malignant clone complexity and the three TIL subtypes over all treatment-naive samples. ES-TIL samples were lower for all four ITH measures relative to S-TIL and N-TIL samples (Figures 3A and 3B ; accounting for tumor purity in the subclonal copy-number comparison) with mixture entropy, heterogeneity index, and subclonal copy number statistically significant. Accordingly, clonally pure tumors had the highest epithelial CD8+ TIL densities ( Figure S4C ). Despite the association between TIL and ITH, clonal similarity between intrapatient sites was not associated with TIL subtype (p > 0.3, nested ranks test; Figure S4D ). For example, omentum sites 1 and 2 from patient 17 had comparable clonal composition, while ovary site 1 contained different clones ( Figure S3) ; however, omentum site 1 was ES-TIL subtype, whereas omentum site 2 and ovary site 1 were N-TIL subtype (Table S2) . Together, these data are consistent with epithelial TIL abundance as a negative determinant of regional malignant clonal complexity.
The negative association between epithelial TIL densities and malignant clone diversity could be explained by clonally complex tumors suppressing development of ES-TIL microenvironments and/or tumor clones undergoing immune-mediated purifying selection in the presence of high epithelial TIL density. In the latter scenario, subclonal (non-ancestral) neoepitopes might serve as targets of T cell recognition and hence show evidence of depletion at ES-TIL sites. To test this, we used NetMHCpan (Ternette et al., 2016) to computationally predict neoepitopes from nonsynonymous somatic SNVs (Table S3) , categorizing each neoepitope as clonal or subclonal through phylogenetic analysis (STAR Methods). For each sample, we then quantified neoantigen depletion by comparing observed to expected (computed on an independent cohort of 121 primary HGSC samples) neoantigen rates (STAR Methods). Within patients, samples with higher epithelial CD8+ density exhibited higher levels of subclonal neoantigen depletion (lower observed/expected subclonal neoantigen rate, p = 0.09, linear mixed model; Table S3 and STAR Methods), but not clonal neoantigen depletion (p > 0.3), compared to other samples from the same patient. This association was pronounced in patients containing samples with the highest epithelial CD8+ TIL densities (p = 0.001, linear mixed model; Figure 3C ). In contrast, no significant association was observed between stromal CD8+ TIL density and clonal or subclonal neoantigen depletion (all p > 0.2, linear mixed model). Thus, samples with high epithelial CD8+ TILs show evidence of immune editing of subclonal neoantigens, raising the possibility that immune-driven purifying selection underlies the observed reduction in malignant cell diversity at TIL-rich sites.
In tumors with high epithelial CD8+ TIL densities, we postulated that the few remaining tumor clones might have avoided immune-related negative selection through clonal expansion of cells lacking neoantigen-or other tumor antigen-presenting HLA alleles. We used a Bayesian statistical extension (STAR Methods) of the LOHHLA algorithm (McGranahan et al., 2017) to analyze WGS data for clone-specific HLA class I allele loss. Of 14 patients evaluated, we identified four patients harboring clonal HLA LOH and four with subclonal HLA LOH (one patient had both; Table S4 ). In three out of four patients with subclonal HLA LOH, the samples with the highest epithelial CD8+ TIL densities contained tumor clones with subclonal HLA LOH ( Figures 3D-3G ), including two of the patients (1 and 15) that demonstrated subclonal neoantigen depletion. An exception was patient 13, where subclonal HLA LOH was observed despite all samples having low epithelial CD8+ TIL density ( Figure 3G ; no samples were ES-TIL). Nevertheless, these findings suggest that tumor clones at ES-TIL sites have, in some cases, escaped immune clearance by somatic genomic loss of HLA haplotypes. We next examined the prevalence of HLA LOH in orthogonal WGS external cohorts (OV-AU, i.e., Patch et al., 2015; . HLA LOH was found in 33.3% of samples (OV-AU: 34.7%, Wang: 32.1%) and was associated with significantly higher expression of lymphocyte markers ( Figure 3H ), establishing a link between HLA LOH and higher TIL levels.
To provide context, we also considered other known mechanisms of immune escape, including anatomic site, disruption of antigen presentation machinery (Yoshihama et al., 2016) , and expression of immunosuppressive factors (Spranger et al., 2013; Rooney et al., 2015) . TIL subtype was not significantly associated with any specific anatomic location (Fisher's exact test, p > 0.05, Table S2 ), and no point mutations, indels, or copy-number losses in antigen presentation machinery molecules were observed in ES-TIL samples. However, consistent with expectation from previous reports (Rooney et al., 2015) , we found that inhibitory immune checkpoint molecules were generally upregulated in tumors with high epithelial CD8+ TIL density ( Figure S4E ). (C) ; Figure S5B ). Similarly, BCR diversity was positively correlated with CD20+ and plasma cell densities (all Spearman p < 0.01; Figure S5C ). S-TIL and ES-TIL tumors had significantly more diverse TCR and BCR repertoires than N-TIL tumors ( Figures 4B, S5D , and S5E) and a higher proportion of rare clonotypes ( Figure S5F ). None of the four ITH measures were significantly associated with TCR or BCR diversity across treatment-naive samples (all Spearman p > 0.3; STAR Methods), indicating that diverse malignant populations do not recruit similarly diverse TIL repertoires.
We next ascertained the degree of homogeneity (similarity) between TCR and BCR repertoires across spatial samples within patients (STAR Methods). This revealed marked variation in both intrapatient TCR and BCR similarity across the cohort ( Figures 4C and S5G ). Considering patients with at least three samples, the extent of intrapatient TCR and BCR repertoire similarities were correlated (Spearman p < 0.1), but with notable exceptions ( Figure S5G ). Patient 15 had high TCR similarity (ranked 2nd out of 20 patients), but not BCR similarity (14th), while patients 10 and 21 had high BCR similarity (3rd and 5th), but not TCR similarity (15th and 20th). Mean intrapatient BCR similarity was not significantly correlated with IHCbased CD20+ or plasma cell density (all Spearman p > 0.2, Figures S5H and S5I) . However, mean intrapatient TCR similarity was strongly associated with CD8+ (Spearman p < 0.01), but not CD4+, TIL density ( Figures 4D and 4E ), suggesting that CD8+ TILs were more broadly distributed (shared) across tumor sites compared to CD4+ TILs. To test this, we trained a classifier to separate TCRs as CD8+ type or CD4+ type on the basis of V/J genes and physicochemical properties of the hypervariable domain (STAR Methods). The ratio of CD8+-/ CD4+-type TCRs was correlated with the ratio of CD8+/CD4+ densities by IHC (Spearman p < 0.01; Figure S5J ). Corroborating our predictions, CD8+-type TCRs were significantly more broadly distributed than CD4+-type TCRs (p < 0.001; Figure 4F ).
Having established that TCR-/BCR-based immune profiles vary across space, we asked how this variation is related to the spatial distribution of tumor clones. Pairwise T cell repertoire similarity was significantly correlated with malignant clone composition similarity in 7 out of 13 patients ( Figure 5 ). Importantly, this relationship was significant in 5 of 6 patients with the highest epithelial CD8+ TIL densities (patients 1, 2, 9, 15, and 17), consistent with T cell clonotypes spatially tracking tumor clones in patients with high epithelial CD8+ TILs. This association held in the same six patients when considering only major TCR clonotypes (most abundant clonotypes constituting the top 50% of reads within each patient), but was only significant in patients 2, 9, and 12 when considering minor clonotypes (all other clonotypes), indicating that the most abundant clonotypes drove this effect. In contrast, pairwise BCR similarity was not significantly correlated with tumor clone similarity in any patient (Figure S3) , suggesting an absence of spatial tracking between B cells and tumor clones.
Mutation Signatures Prognostically Associate with Patient-Level Immunologic Features
We next investigated interaction of malignant and immune infiltration from the perspective of mutational processes operating in HGSC. We previously identified two prognostically relevant mutation signature-associated subtypes: H-HRD and H-FBI . Here, we explored whether those subtypes could explain the observed variation in immune infiltration within and between patients. We pooled WGS data from our 21 cases with 195 additional single-site ovarian cancer cases (133 from Wang et al., 2017 and 62 from OV-AU in the International Cancer Genome Consortium [ICGC] ) and applied a novel multimodal correlated topic model (MMCTM; Funnell et al., 2018) , identifying six SNV and seven rearrangement signatures (Figures S6A and S6B and Table S5) . Hierarchical clustering by signature proportions identified four major clusters ( Figure 6A , Table S5 , and STAR Methods): one subtype (HRD-DEL) dominated by the point mutation signature associated with homologous recombination deficiency (P-HRD) along with a short deletion signature (R-SDEL) associated with BRCA2 mutations (Nik-Zainal et al., 2016) , a second subtype (HRD-DUP) with P-HRD and a short tandem duplication signature (R-SDUP) associated with BRCA1 mutations (Nik-Zainal et al., 2016) , a third subtype (FBI) characterized by an FBI rearrangement signature (R-FB) associated with breakage-fusion-bridge , and a fourth, minor subtype distinguished by medium and large See also Figure S4 and Tables S2, S3 , and S4. (C) , (D) , (E), and (F). See also Figure S5 and Table S2 . See also Figure S3 and Table S2 .
A B C D E
(legend on next page) tandem duplications (TDs) (R-MDUP and R-LDUP, respectively) associated with CDK12 point mutations (Popova et al., 2016; Funnell et al., 2018) . Using this grouping of samples, we asked how immune response characteristics co-segregated with mutational signatures. Unlike TIL subtypes, mutational subtypes were largely invariant within patients ( Figures S6C and S6D ), indicating that mutational processes cannot explain intrapatient heterogeneity in TIL subtypes. We next asked whether mutational subtypes related to the mixture of TIL subtypes within each patient. Focusing on the ES-TIL subtype, we categorized patients with multi-sample IHC data as ES-none (no ES-TIL samples), ESmixed (both ES-TIL and N-TIL/S-TIL samples), or ES-pure (all samples ES-TIL). The HRD subtypes contained the only three ES-pure patients (out of 12 HRD patients), although this did not reach significance with respect to the other mutational subtypes (Fisher's exact test, p = 0.23; Figure 6B ). Expression values of immune-associated pathways (Cesano, 2015) for 54 OV-AU cases (STAR Methods) revealed that cytotoxicity, antigen processing, cytokine, and T cell markers were highest among HRD tumors ( Figure 6C ), concordant with similar findings in ER+ breast cancer (Smid et al., 2016) and among BRCA1-mutated tumors in HGSC (Nelson, 2015) . Relative to HRD tumors, TD tumors had similar expression of immune markers, whereas FBI tumors were significantly depleted of these (Figure 6C) . Corroborating these findings, differential expression analysis of OV-AU cases revealed that antigen processing, TCR/BCR signaling, cytotoxicity, and cytokine pathways were upregulated in HRD and TD relative to FBI (Q < 0.01), while none of these were differentially expressed between HRD and TD ( Figure S7 and Table S6 ).
Colocalized foldback inversions and focal high-level amplifications (HLAMPs), thought to be reflective of breakage-fusionbridge, have been associated with poor outcomes in HGSC . We asked whether immune activity could be used to further stratify foldback-enriched tumors into subgroups with distinct survival outcomes. Using gene expression data for 433 ovarian cystadenocarcinoma cases from the Cancer Genome Atlas (TCGA; Bell et al., 2011 ; Table S7 ), we jointly modeled the effects of colocalized foldback-HLAMP events and cytotoxicity expression with a Cox proportional hazards model, controlling for age of diagnosis and therapeutic regimen (STAR Methods). In agreement with Wang et al. (2017), high levels of colocalized foldback-HLAMP events were associated with significantly shorter overall survival (hazard ratio: 1.64, 95% CI: 1.06-2.52, p < 0.05; Figure 6D ). The association between cytotoxicity and survival differed between FBI-HLAMP groups (p < 0.05, likelihood ratio test between Cox models with and without cytotoxicity 3 FBI-HLAMP interaction). In cases with no HLAMP events, cytotoxicity was significantly associated with a decreased hazard ratio (0.52, 95% CI: 0.29-0.92, p < 0.05; Figure 6D ). However, among cases with colocalized foldback-HLAMP events, the hazard ratio for cytotoxicity was not significant (FBI-AMP low: 0.97, 95% CI: 0.71-1.34, p > 0.3; FBI-AMP high: 1.24, 95% CI: 0.91-1.69, p > 0.1; Figure 6D ), suggesting that HLAMP-positive foldback-containing tumors harbor prognostic effects that are independent of immune response. We then median-stratified cases into low-and high-cytotoxicity groups. Low FBI was associated with significantly longer overall survival among tumors with high cytotoxicity (log-rank p < 0.05; Figure 6E ), but not low cytotoxicity (log-rank p > 0.2; Figure 6E ). Together, the covarying effects of immune activity and mutational processes suggest a combinatorial prognostic effect with high immune activity and low prevalence of FBIs leading to the best outcomes, while FBI-bearing patients have poor outcomes even in the presence of high immune activity.
DISCUSSION
Our results illuminate evolutionary properties at the malignantimmune interface of HGSC. In patients with the highest epithelial TIL densities, our data are consistent with active pruning of malignant cell diversity by TIL through subclonal neoepitope recognition, resulting in expansion of clones harboring neoantigen loss and/or HLA LOH. The underlying mechanism likely involves tracking of tumor clones across peritoneal space by T cell clones, but not B cell clones. As such, immune infiltrates impose selective constraints, shaping patterns of malignant spread and clonal diversity in HGSC. Our findings do not exclude the possibility that T cells can also recognize clonal neoepitopes (McGranahan et al., 2016) ; however, subclonal neoepitopes, which have been reported to have higher predicted immunogenicity than clonal neoepitopes (Jimé nez-Sá nchez et al., 2017), may be under stronger negative selection. Moreover, depletion of clonal neoantigens could result in complete tumor elimination and therefore go clinically undetected.
The presence of extensive intrapatient immune variation prior to treatment highlights potential shortcomings of prognostic stratification and study of the immune microenvironment from single biopsies. The widespread multi-site variation we observed suggests that even a single site harboring relative immune privilege may be sufficient to engender resistant disease, regardless of active immune responses in distal intraperitoneal regions. We suggest immunologically sheltered havens may plausibly act as S6 and S7 and Tables S5, S6 , and S7. reservoirs of clonal diversity from which malignant clones impacting disease relapse might emerge. As a preliminary illustrative example, ES-pure patients had better outcomes (5 of 6 no evidence of disease [NED] or alive with disease [AWD], 5 of 6 platinum sensitive, median progression-free survival [PFS] for relapsed patients was 19 months) than ES-mixed and ES-none patients (8 of 11 and 11 of 14 NED or AWD, 7/9 and 7/11 platinum sensitive, median PFS for relapsed patients was 9.3 and 7.1 months, respectively).
Our data show for the first time a prognostically relevant interaction between mutational processes and immune response in HGSC. Notably, foldback inversions associate with poor outcomes, even in highly cytotoxic tumor microenvironments. Thus, in contrast to point mutations resulting from mismatch repair deficiency (Le et al., 2015) , FBIs likely represent a class of non-immunogenic genomic aberrations. Conversely, our findings also provide context for explaining superior outcomes observed in BRCA1-and BRCA2-mutated HGSC (Nelson, 2015) . In contrast to previous reports that BRCA1 disruption, but not BRCA2 disruption, is associated with elevated TILs (Nelson, 2015; Goode et al., 2017) , we observe comparably high immune activity between BRCA1-associated (HRD-DUP), BRCA2-associated (HRD-DEL), and TD subtypes. Shared deficiencies in homologous recombination between HRD and TD subtypes (Joshi et al., 2014) may result in patterns of rearrangements or point mutations responsible for eliciting these immune responses (Smid et al., 2016) .
Our study provides context for clinical trials investigating various classes of immunotherapy in ovarian cancer (e.g., immune checkpoint blockade, adoptive T cell transfer, neoepitope vaccination, combination immunotherapy with PARP inhibition). A recent case study tracking immune response over time in a HGSC patient with a remarkable clinical trajectory (Jimé nez-Sá nchez et al., 2017) demonstrated that spatiotemporal variation of the immune microenvironment relates specifically to treatment sensitivity of malignant clones. We reveal that immunemicroenvironment spatial variation exists prior to treatment and is prevalent in the HGSC patient population. Given that efficacy of PD-1 axis blockade hinges on pre-existing adaptive immunity (Herbst et al., 2014) , immunologically privileged sites on an otherwise highly infiltrated background may explain the limited success of immunotherapy in HGSC to date (Homicsko and Coukos, 2015; Gaillard et al., 2016) . While some tumors contain abundant TILs, lack of cancer cell-lymphocyte colocalization and reduced tumor-immune engagement in S-TIL sites may result from a failure of immune recognition or region-specific barriers to infiltration. Consequently, TIL abundance alone is an insufficient predictor of active immune response. Even at sites patterned by extensive epithelial TILs, neoantigen depletion and apparent positive selection of clones harboring HLA LOH may render checkpoint blockade ineffective.
Despite these challenges, our findings inform on several potential therapeutic solutions. While FBI cases exhibit poor prognostic profiles independently of immune properties, HRD cases, typically associated with fewer foldback inversions, likely represent optimal candidates for immunotherapy approaches. Thus, mutational processes considered in conjunction with immune properties will aid in interpretation of newly initiated clinical trials examining combination PARP inhibition with checkpointblockade approaches. Furthermore, if obstacles to infiltration at immunologically privileged sites can be surmounted, our findings hint at the tantalizing potential that such tumor sites may represent targetable cancer cell populations, owing to their limited neoantigen and HLA depletion at baseline.
As the cancer evolution field progresses toward a more rigorous understanding of the fitness of heterogeneous clones within disease spectra and over temporal dimensions (Lipinski et al., 2016) , external selective pressures imposed by the immune system must be considered as highly relevant factors. Here we show that high-resolution measurement of the immune microenvironment together with clonal decomposition analysis is tractable and yields novel insight into forces shaping malignant cell diversity and intraperitoneal spread. Broadly disseminated intraperitoneal disease at diagnosis in HGSC remains a formidable clinical problem. Our study informs on how regional variation at the interface of immunological and cancer cells controls dissemination and diversification of clones and simultaneously identifies microenvironmental and malignant cell properties to exploit in future immuno-oncologic therapeutic strategies for HGSC.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Sohrab P. Shah (sshah@bccrc.ca).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Sample acquisition, consent, & surgery Ethical approval for this study was obtained from the University of British Columbia (UBC) Research Ethics Board. Women (biological sex: XX) undergoing debulking surgery (primary or recurrent) for carcinoma of ovarian/peritoneal/fallopian tube origin were approached for informed consent to bank tumor tissue. Cases of high-grade serous carcinoma where more than one sample was collected were chosen for this analysis. Clinicopathologic and outcome data were collected by chart review. Consistent with the practice at UBC and BC Cancer, all patients with high-grade serous ovarian cancer (HGSC) are referred to the hereditary cancer clinic and offered genetic testing for BRCA1 and BRCA2 mutations (http://www.bccancer.bc.ca/screening/Documents/ HCP_GuidelinesManuals-HBOCCriteria.pdf).
For consented patients, when multiple tumor sites were encountered intraoperatively, effort was made to bank as many sites as possible. Samples were flash frozen and stored according to conditions outlined below. For cases where multiple tumor sites were encountered but not all anatomic sites could be frozen (e.g., due to unavailability of trained staff), archival specimens stored within our pathology department were used. All samples were from removed structures during attempts at optimal debulking; hence the majority of samples were from omentum and ovarian sites.
Platinum sensitive is defined as no relapse within 6 months of the chemotherapy stop date.
Sample preservation & histologic evaluation
When adequate tumor volume was available, multiple tissue samplings were obtained from each tissue specimen. Up to 5 samplings were taken from a given tumor, with effort made to equally space samples while staying within grossly apparent tumor tissue. Each sampling was cut into three pieces, yielding two end-pieces for cryovials and a middle portion placed in 10% buffered formalin. End pieces were homogenized manually and with a paddle blender (Stomacher). All paraffin-embedded blocks, including formalin-fixed tumor samples and molecular-fixed fallopian tubes, were sectioned and stained with hematoxylin and eosin prior to expert histopathological review to confirm the presence of high-grade serous carcinoma. Pieces from the same sampling were given the same sample identifier for the analysis steps described below.
Distribution and availability of samples
Investigators interested in the use of samples from this study should contact the Lead Contact for further information.
METHOD DETAILS WGSS library construction & sequencing
Frozen tumor samples from 14 patients (patients 11-17, 25, 26, 28-32, total 71 samples) were submitted for library construction and sequencing. Sample size was determined by availability of resectable, cryopreserved tissue, and DNA quality. For all tumor and normal samples, DNA extraction was followed by library construction and sequencing using Illumina HiSeq2500 whole genome shotgun v4 chemistry with paired-end 125bp reads. Samples were sequenced to an average of 96X coverage. Patients 1-4, 7, 9, and 10 were previously sequenced according to specifications described in McPherson et al. (2016) . (Table S1 ). SNVs were sampled as evenly as possible across nodes. Data for patients 1-4, 7, 9, and 10 was obtained from McPherson et al. (2016) , and used as input for section Clonal analysis onward. Primer design Primers targeting the positions described above were designed using primer3. The full list of primers is included in Table S1 . Optimal primer length was 27nt (18-30nt) and products were designed to be 150-250nt long with 53-61 C melting temperature. Breslauer thermodynamic correction and Schildkraut and Lifson salt correction settings in primer3 were used. Additionally, primers targeting SNVs were required to pass the following preliminary filters: minimum of 5 alignments to the genome as given by BLAT for each primer, and each primer position at least 30nt away from the target SNV.
Targeted bulk sequencing analysis
Primers were additionally tested using a combination of UCSC's in silico PCR tool (http://genome.ucsc.edu/cgi-bin/hgPcr) aligned against the reference hg19 genome and custom in-house code (Canada's Michael Smith Genome Sciences Centre) to verify a unique hit and check that the variant was located within 150bp of the nearest end of the amplicon to ensure coverage in an Illumina NextSeq 150bp paired end read. The primers were tagged with Illumina adapters to enable a direct sequencing approach that precludes the need for adaptor ligation during sample preparation. The Illumina adaptor tags were: 5 0 -CGCTCTTCCGATCTCTG-3 0 on the forward amplicon primer and 5 0 -TGCTCTTCCGATCTGAC-3 0 on the reverse amplicon primers. PCR and Illumina sequencing Genomic DNA templates were used as starting material to generate PCR products. PCR was set up using Phusion DNA polymerase (Fisher Scientific, USA) according to the manufacturer's specifications. The standard PCR conditions used were an initial denaturation at 98 C for 30 s, followed by 35 cycles of 98 C for 10 s, 60 C for 15 s and 72 C for 8 s, and a final extension at 72 C for 10 minutes.
Amplicons were pooled by template for sequencing sample preparation. Sample preparation involved a second round of amplification using Phusion DNA polymerase with 6 PCR cycles using PE primer 1.0-DS (5 0 -AATGATACGGCGACCACCGAGATC TACACTCTTTCCCTACACGACGCTCTTCCGATCTCTG-3 0 ) and a custom PCR Primer (5 0 -CAAGCAGAAGACGGCATACGAGATN NNNNNGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTGAC-3 0 ) that contains a unique six-nucleotide 'index' shown as N's. PCR products were cleaned up using PCRClean DX beads (Aline Biosciences, USA). DNA quality was assessed using the Caliper LabChip GX High Sensitivity Assay (Caliper Life Sciences, USA) and DNA quantity was measured using a Qubit dsDNA HS assay kit on a Qubit fluorometer (Life Technologies, USA).
The indexed libraries were pooled together and sequenced on the Illumina NextSeq500 platform with paired-end 150bp reads using v2 chemistry reagents.
Immunohistochemistry
All reagents were from Biocare Medical (Pacheco, CA) unless otherwise stated. Slides of formalin-fixed, paraffin embedded tissue were deparaffinized and rehydrated through xylene and graded alcohols. Antigen retrieval was performed using Diva Decloaker in a Biocare decloaking chamber at 125 C for 30 s. Slides were then rinsed with water, marked with PAP pen and loaded into the Biocare Intellipath FLX autostainer. Slides were blocked with peroxidazed-1 and background sniper for 5 minutes and 10 minutes respectively then a cocktail of either CD8 (1/250, clone C8/144B, Cell Marque, Rocklin, CA) and CD3 (1/500, clone SP7, Spring Biosciences, Pleasanton, CA), or CD79a (1/400, clone SP18, Spring Biosciences, Pleasanton, CA) and CD138 (1/200, clone B-A38, Biocare Medical, Pacheco, CA) in Da Vinci Green diluent was added for 30 minutes at room temperature. Following a wash step, Mach2 Doublestain #2 polymer was added for 30 minutes at room temperature and then antigens detected with IP Ferengi Blue chromogen for 7 minutes followed by IP DAB chromogen for 5 minutes. To denature the first round of antibodies, slides were removed from the autostainer and placed in pre-warmed SDS-glycine pH 2.0 solution for 45 minutes at 50 C with periodic agitation. Slides were then washed with water and replaced in the autostainer for the 2nd round of staining. CD20 (1/300, clone L26, Biocare Medical, Pacheco, CA) diluted in Da Vinci Green diluent was added to the slides and incubated for 30 minutes at room temperature. Mach2 Mouse-AP polymer or Mach2 Rabbit-AP polymer was added for 30 minutes at room temperature to detect CD20. Warp red chromogen was added to the slide for 7 minutes, hematoxylin at a 1/5 dilution was then added for 5 minutes. The slides were then washed, air-dried and coverslipped with Ecomount coverslipping medium.
Nanostring gene expression FFPE samples were deparaffinised with xylene and washed with 100% ethanol. Tissue was then extracted using QIAGEN miRNeasy FFPE Kit, following the protocol for purification of total RNA (including miRNA) from FFPE tissue sections. RNA quality was assessed with Nanodrop. 500ng of high quality RNA (260/280 ratio of 1.7-2.3 and A260/230 ratio of 1.8-2.3) for each sample was used in the Nanostring assay (PanCancer Immune Profiling panel (Cesano, 2015) additionally containing markers for high-grade serous ovarian cancer subtypes C1, C2, C4, and C5 (Leong et al., 2015) ). Data was normalized with the voom function from the R package limma and TMM normalization. Samples flagged by nSolver (Nanostring Technologies) were removed from further analysis.
TCR & BCR sequencing
In the text below, TRB and IGH refer to TCR-b chain and Ig-heavy chain, respectively. RNA was extracted from frozen tissue using the miRNeasy Mini kit. Quality (260/280) and quantity were determined using Nanodrop. Total RNA samples were also QC checked using the Caliper HT RNA HiSens assay (Caliper Life Sciences, USA). Samples ranging from 60-255ng RNA were re-arrayed into a 96-well plate. First-strand cDNA was synthesized from the total RNA samples using the SMARTScribe Reverse Transcriptase from Clontech, BNA oligo, TRB and IGH gene specific primers at a concentration of 0.5uM. Reactions were incubated on a tetrad using the following program: 90mins at 42 C, 15mins at 70 C and 2mins at 4 C. Using cDNA as a template, first round PCR for TRB and IGH was set up using Phusion DNA polymerase (Fisher Scientific, USA) according to manufacturer's specifications. The gene specific primers used were TRB 5 0 -TCTCTGCTTCTGATGGCTCAAAC-3 0 and IGH 5 0 -ACACCGTCACCGGTTCGG-3 0 . The PCR conditions used were an initial denaturation of 98 C for 30 s, followed by 35 cycles of 98 C for 10 s, 55 C for 10 s and 72 C for 20 s, and a final extension at 72 C for 5 minutes. PCR products were size selected and cleaned up using PCRClean DX beads (Aline Biosciences, USA). Using first round PCR product as a template, a nested round of PCR for TRB and IGH was set up using Phusion DNA polymerase (Fisher Scientific, USA) according to manufacturer's specifications. The gene specific primers used were TRB 5 0 -TGCTCTTCCGATCTGACAGCGACCTCGGGTGGGAACA-3 0 and IGH 5 0 -TGCTCTTCCGATCTGACAAGACSGATGGGCCCTTGGT-3 0 . The PCR conditions used were an initial denaturation of 98 C for 30 s, followed by 10 cycles of 98 C for 10 s, 65 C for 10 s and 72 C for 20 s, and a final extension at 72 C for 5 minutes. PCR products were cleaned up using PCRClean DX beads (Aline Biosciences, USA).
TRB and IGH amplicons were pooled by template for sequencing sample preparation. Sample preparation involved a second round of amplification using Phusion DNA polymerase with 6 PCR cycles using PE primer 1.0-DS (5 0 -AATGATACGGCGACCACC GAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTCTG-3 0 ) and a custom PCR Primer (5 0 -CAAGCAGAAGACGGCATAC GAGATNNNNNNGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTGAC-3 0 ) that contains a unique six-nucleotide 'index' shown here as N's. Products were cleaned up using PCRClean DX beads (Aline Biosciences, USA). DNA quality was assessed using the Caliper LabChip GX High Sensitivity Assay (Caliper Life Sciences, USA) and DNA quantity was measured using a Qubit dsDNA HS assay kit on a Qubit fluorometer (Life Technologies, USA).
The indexed libraries were pooled together and sequenced on the Illumina HiSeq platform with paired-end 250bp reads using v2 chemistry reagents.
QUANTIFICATION AND STATISTICAL ANALYSIS WGSS analysis Alignment
Reads were aligned to the hg19 reference genome downloaded from http://www.bcgsc.ca/downloads/genomes/9606/hg19/ 1000genomes/bwa_ind/genome/GRCh37-lite.fa. Alignments were performed using bwa (Li and Durbin, 2009) using the aln and sampe commands. Duplicates were flagged with Picard http://broadinstitute.github.io/picard/. SNV and indel calling Somatic SNVs were called using both Strelka 1.0.14 (Saunders et al., 2012) and MutationSeq 4.2.0 (Ding et al., 2012) with default parameters. Somatic indels were additionally called with Strelka. We considered a somatic SNV high quality if it was predicted by both MutationSeq and Strelka to be present in any sample from a patient, not necessarily the same sample for each program. Germline SNVs and indels were called with samtools mpileup and bcftools call 1.4.1, with default parameters.
Gene name, predicted effect and impact of SNVs and indels were annotated using SnpEff 4.0e. Mappability scores were annotated for each position using precomputed values downloaded from UCSC (http://hgdownload-test.cse.ucsc.edu/goldenPath/hg19/ encodeDCC/wgEncodeMapability/release3/wgEncodeCrgMapabilityAlign50mer.bigWig). For downstream analysis we only considered variants with a mappability score > 0.99.
Breakpoint calling
We used deStruct (McPherson et al., 2017a) and lumpy (https://github.com/arq5x/lumpy-sv) to call breakpoints from WGS data. deStruct breakpoints were filtered for those with at least 2 discordant reads, and at least 2 split reads. Additional filters removed breakpoints for which the reconstructed sequence was less than 120nt, and removed breakpoints with read data likelihood less than À20. Following this, the intersection of deStruct and lumpy predictions was taken, and events lying within poor mappability regions, with break distance % 30bp, and deletions with breakpoint size < 1000bp were excluded . Furthermore, breakpoints overlapping germline structural variation as determined from the database of genomic variants or identification of a similar event in the matched normal sample. Classification of breakpoint and rearrangement type was performed according to .
Copy number calling
We applied ReMixT (McPherson et al., 2017b) to predict allele and clone-specific copy number from WGS samples. ReMixT jointly infers clone and allele specific copy number of both segments and breakpoints, allowing for increased statistical strength for detecting subclonal rearrangements associated with subclonal copy number changes. Additionally, ReMixT uses haplotype blocks obtained from phased SNPs to increase the power for detecting small allelic imbalances resulting from subclonal copy number changes. ReMixT was run on each patient's full set of WGS samples with default parameters. Accurately inferred clone specific segment copy number was used to calculate the length-normalized proportion of segments predicted with divergent clonal copy number.
In order to call high-level amplification (HLAMP), we employed identical methods to . We ran TITAN (Ha et al., 2014) on WGS data to infer logR values; HLAMP was called for segments with median logR values > 1. Identifying BRCA variants Point mutations and indels in BRCA1 and BRCA2 were called from germline and somatic WGS data, as described above. Variants with high SnpEff-annotated impact were used. Somatic BRCA status was determined from variant calls. Where available, clinical test results were used to determine germline BRCA status; germline variant calls were used for patients that did not consent to clinical testing. Clinically-determined BRCA status is shown in (Table 1) .
Clonal analysis Mutation cluster inference
We ran PyClone 0.13.0 (Roth et al., 2014) in multi-sample mode to perform initial clonal analysis. Parental copy number and tumor content estimates from ReMixT along with reference and alternative allele counts from deep sequencing data of SNVs (PCR and Illumina sequencing) were used as input for PyClone. The following SNVs were filtered out for clonal analysis: germline SNVs, SNVs absent (probability < 0.01) in all samples in a patient (probabilities computed from a binomial test, assuming a sequence error rate of 0.001), and SNVs on sex chromosomes. The MCMC chain was run for 100,000 iterations, with a burn-in of 50,000. Posterior plots were visually inspected to confirm convergence. Flat cluster assignments were produced from posterior similarity matrices using the MPEAR method described in Roth et al. (2014) . SNVs with broad posterior cellular prevalence distributions (width of 95% credible interval R 0.2) far from the corresponding cluster median (difference of % 0.05) were excluded from further analysis. Additionally, clusters absent or present at low prevalence in all samples (median cluster prevalence across SNVs % 0.05 in all samples), with only one SNV, or with R 50% SNVs lost were filtered out.
Archival samples without a corresponding flash frozen sample (i.e., no copy number predictions) were excluded from this initial analysis. They are reintroduced in section Clonal phylogenies & postprocessing.
Clonal phylogenies & postprocessing
Filtered PyClone results were provided as input to LICHeE, a multi-sample cancer lineage inference method (https://github.com/ viq854/lichee), to elucidate clonal phylogenies. LICHeE was run in cellular prevalence mode (-cp), with additional options -completeNetwork -sampleProfile. Other parameters were set to the defaults. The top ranking lineage tree from LICHeE was kept.
To remove artifacts (e.g., falsely called low prevalence clones) and obtain clonal prevalences for archival samples, clonal prevalences were refined by resampling alternative and reference allele counts for deeply sequenced tumor samples and matched peripheral blood (normal) according to the following Bayesian generative model, adapted from McPherson et al. (2016) . We suppress indices for samples as these can be treated independently.
We assume that the alternative allele counts of SNV n in the matched normal and tumor samples, b correspond to the total read depth of SNV n in the normal and tumor sample, respectively, p n normal is the probability of observing the alternative allele of SNV n in the normal sample, s tumor is the dispersion parameter, Z n is the cluster membership of SNV n, and x nc , using similar notation to Roth et al. (2014) , is given by:
where j n is the copy number genotype of SNV n in the tumor variant population, t is tumor content, cðg N Þ = 1 is the copy number genotype of the alternative allele in the normal population, total copy number T n = 2ð1 À tÞ + j n t, and f c is the cellular prevalence of PyClone cluster c, which can be expressed as the summation of clonal prevalences f j over clones that contain PyClone cluster c. That is:
where G c j is a binary indicator of whether clone j contains PyClone cluster c. We then assume the following distributions over the parameters in Equations (1) and (2):
with k the Dirichlet parameter as defined in McPherson et al. (2016) , and s normal the dispersion parameter. The value z corresponds to twice the mean allelic fraction of alternative alleles in the normal sample (twice because we model cðg N Þ = 1). In essence, our model is analogous to that of McPherson et al. (2016) , but we now consider the probability of sampling a variant allele from non-tumor cells to be nonzero, equal to p n normal , rather than 0. Informally, the model can be described as follows. For each tumor sample:
1. Generate clonal prevalences 2. Compute the cellular prevalence of a mutation n by summing the prevalences of all clones containing the PyClone cluster associated with n 3. Generate the SNV-specific normal contamination fraction p n normal and allelic count data for the matched normal sample 4. Based on the contamination fraction, apply a modified PyClone likelihood model to simulate allelic count data in the tumor sample
The normal contamination fraction can be interpreted as the allelic fraction of SNV n in the matched normal, likely due to sequence errors or contamination. Samples with low tumor purity are particularly confounded by these issues; the addition of step 3 and modification of step 4 relative to McPherson et al. (2016) helps eliminate erroneously identified rare clones in these samples.
We set the following hyperparameter values: s tumor = s normal = 200 and k as a repeating vector of 0.01. The effect of our setting for k is to assume clonal purity unless there is substantial evidence for the contrary.
The Hamiltonian Monte Carlo chain was run for 10,000 iterations, with an additional burn-in of 5000. Posterior plots were visually inspected for convergence. Clones falling below a prevalence threshold (< 90% of the posterior distribution of clonal prevalence > 0.01) were removed.
Due to difficulties in lineage construction for patients with several samples composed of divergent clonal lineages (McPherson et al., 2016) , results for patients 3 and 9 were taken from previously analyzed single-cell sequencing data (McPherson et al., 2016) . Clonal architecture distance Pairwise similarity between clonal compositions (within a given patient) was computed using a modified version of the weighted uniFrac measure, to simultaneously incorporate clonal architecture and phylogeny information. First, clonal phylogenies from Clonal phylogenies & postprocessing were taken as ground truth and used to recompute cellular prevalences for all SNVs (denoted here as j a and j b ) determined by WGS, where a and b denote the samples being compared. Clonal distance was computed as the summation of the differences in cellular prevalences across SNVs, or equivalently jjj a À j b jj 1 .
Measures of intratumoral heterogeneity
Sample mixture entropy and clone divergence were defined as in McPherson et al. (2016) . In order to compute divergence, SNVs from WGS data were assigned to PyClone clusters -and transitively, clones -by maximum likelihood according to the PyClone likelihood model (Roth et al., 2014) . Proportion subclonality (copy number based measure) was computed as the proportion of the genome with subclonal copy number according to results from ReMixT. Heterogeneity index, a combined measure of intratumoral heterogeneity incorporating both clone prevalences and phylogenetic relationships, was computed as the sum of relative phylogenetic divergence between all pairs of distinct clones, weighted by clonal prevalence. The heterogeneity index is the mean phylogenetic divergence between a randomly selected pair of tumor cells from a sample (based on inferred clonal composition). Formally, for a sample A with clone set CðAÞ = fc i g and corresponding prevalences p i (where 0 < p i < 1; P i p i = 1): 
where S ci is the set of WGS SNVs assigned to clone c i . By construction, the heterogeneity index takes values between 0 and 1. Intratumoral heterogeneity values for each sample are listed in Table S2 .
Samples were also assigned to clonal mixture classes (pure, chain, branched) based on the phylogenetic relationships between constituent clones. Pure samples contained a single clone; chain samples contained clones along a single lineage (in other words, the minimal spanning tree is a line); branched samples contained at least 2 clones that were not ancestors/descendants of each other (in other words, the minimal spanning tree contains a bifurcation).
The significance of differences in the 3 clone-derived intratumoral heterogeneity measures (entropy, clone divergence, heterogeneity index) between the 3 TIL subtypes was assessed with the Kruskal-Wallis test ( Figure 3A) . Post hoc comparisons were made with Dunn's test (P-values were BH corrected).
To assess the significance of differences in subclonal copy number proportion between the 3 TIL subtypes, ANOVA was performed (aov function in R) with subclonal CN proportion as the dependent variable (logit-transformed, as subclonal CN proportion values lie between 0 and 1, exclusive), TIL subtype and cellularity as independent variables (to control for tumor cellularity). The residual plot did not indicate any substantial deviations from normality, with relatively constant variance across the fitted range. Post hoc comparisons were made with Tukey's range test (P-values were BH corrected).
RNA-seq analysis RNA-seq raw counts for 54 primary HGSC tumors from the Australian Ovarian Cancer Study (OV-AU) (Patch et al., 2015) were downloaded from the International Cancer Genome Consortium (ICGC) Data Portal. Ensembl Gene IDs were mapped to gene symbols using biomaRt. Duplicate entries were summarized by taking the mean of expression values. Raw counts were normalized using voom from the R package limma with quantile normalization. Table S5 ). Note that a POLE hypermutant (one of the endometrioid cases) was excluded from the original set of 133 cases described in , and while 93 cases were available from the Australian Ovarian Cancer Study, only 62 had BAM files on the data portal. Similarly processed variant calls to WGSS analysis were obtained from . In order to avoid counting the same variant more than once, the union of SNVs from all samples for each multi-site HGSC patient was analyzed together as a 'meta-sample'. Signature inference & clustering Signatures and proportions were inferred from WGS SNV and rearrangement (structural variation, SV) calls (section WGSS analysis) by applying the multimodal correlated topic model method (Funnell et al., 2018) . For SNVs, the pentanucleotide context of each variant is considered. Rearrangements (deletions, duplications, inversions, and foldback inversions) were binned by breakpoint distance (<10kb, 10kb-100kb, 100kb-1Mb, 1Mb-10Mb, >10Mb) and microhomology length (Nik-Zainal et al., 2016; Funnell et al., 2018) . The optimal number of SNV and SV clusters was determined using the elbow method on model log-likelihoods (Funnell et al., 2018) . The probable identity of each point mutation signature is as follows: P-MMR-1 4 mismatch repair (MMR), P-HRD 4 homologous recombination deficiency (HRD), P-UM 4 ultramutator-associated mutation signature (present at very low levels in the HGSC samples; primarily observed because of an endometrial sample from Wang et al. (2017)), P-APOBEC 4 APOBEC, P-AGE 4 age signature, and P-MMR-2 4 uncertain, but with a strikingly similar T/C substitution pattern to the MMR signature. Sample-specific and non-ancestral mutation signatures were calculated by adding signature assignment weights for all constituent variants. For nonancestral analysis ( Figure S6D ), non-ancestral SNVs were defined as those not present (and not called as ancestral) in all samples from that patient, and samples with fewer than 50 non-ancestral SNVs or SVs were excluded. Prior to clustering ( Figures 6A, S6C , and S6D), signature proportions were scaled across the entire pooled cohort to a standard Gaussian distribution. Hierarchical clustering was performed with Ward's method and a Pearson correlation-based distance measure (d = (1-r)/2, where r is the Pearson correlation coefficient). For patients in the discovery cohort with more than 2 samples, molecular subtype annotations on the heatmap correspond to the mode of subtype assignments for each patient. The 4 described subtypes (HRD-DEL, HRD-DUP, FBI, and TD) were recovered using the dynamicTreeCut R package (or equivalently, by cutting the dendrogram into 4 clusters). Association with immune markers RNA-seq expression data (see RNA-seq analysis, Nanostring analysis) from a set of 54 untreated primary OV-AU cases was used for the comparison depicted in Figure 6C . Differential gene expression Differential gene expression analysis between mutation signature clusters for ICGC OV-AU cases (see RNA-seq analysis) was carried out using the limma method (R package). limma results for HRD versus FBI, TD versus FBI, and HRD versus TD contrast matrices were fed as input to the R package GAGE for gene set enrichment analysis using KEGG pathways. Pathways significantly up-or downregulated with Q < 0.01 were regarded as significant. Results of differential expression analysis are shown in Figure S7 and Table S6 . TCGA foldback inversions A set of n = 433 TCGA ovarian serous cystadenocarcinoma cases with complete copy number, clinical, hg19 exome BAM files, and array-based gene expression data was selected for analysis (Bell et al., 2011) . Selected TCGA cases are listed in Table S7 . Expression data was downloaded from the TCGA data portal and clinical data was downloaded from the TCGA Pancancer project under Synapse (ID: syn1461171).
Mutation signature analysis
Array gene expression data was preprocessed with the voom function from limma (R package), using quantile normalization. The median of normalized expression values for genes associated with cytotoxicity (derived from Nanostring PanCancer Immune Profiling Panel annotations (Cesano, 2015) ) was computed. Samples were stratified into immune-high and immune-low classifications by thresholding on median cytotoxicity score across the cohort (Table S7 ). To threshold on FBI status, foldback-amplification colocalization status (FBI-AMP High, FBI-AMP Low, No AMP) for all cases was retrieved from . We performed a survival analysis on FBI groups after subsetting by immune cluster. The log-rank test was used to compare survival outcomes between subgroups.
A Cox proportional hazards model was also fit to the overall survival data, using foldback-amplification colocalization status as a discrete explanatory variable, interaction terms between cytotoxicity score and FBI-HLAMP status, along with control variables for age of pathologic diagnosis and treatment regimen (columns immunotherapy, additional immunotherapy, additional drug therapy, and additional chemotherapy in the Synapse table). Age of diagnosis was binned into < 50, 50-70, and > 70 categories, and along with immunotherapy and additional chemotherapy used as stratification variables (as these originally violated the proportionality assumption). Patients without available data for age of diagnosis (5) were excluded. To assess the validity of the proportional hazards assumption, the cox.zph function the survival R package was used. None of the individual proportionality assumption tests or the global test were violated.
The R formula for the model was: coxph(survival $ mutation_signature_subgroup + cytotoxicity:mutation_signature_subgroup + strata(age_binned) + strata(immuno_ therapy) + strata(additional_chemo_therapy) + additional_drug_therapy + additional_immuno_therapy, data)
To evaluate the significance of the model including the cytotoxicity 3 FBI-HLAMP interaction term, we constructed an identical model, but with a cytotoxicity score as an explanatory variable without the interaction terms with FBI-HLAMP. A likelihood ratio test was performed on the resulting fits of the 2 models.
Immunohistochemistry analysis
Tissue segmentation & cell counting Slides were scanned using the Vectra Multispectral Imaging System (Perkin Elmer) and 20 random 20X images (high-powered fields, HPFs) collected for each sample. The resulting multispectral images were then analyzed using Inform software (Perkin Elmer) with the resulting cell segregation data consolidated using Spotfire (Tibco). Phenotyping algorithms were created by 2 independent researchers (K.M., S.L.) and the results validated by a 3rd researcher (A.W.Z.) . Briefly a training set of 10 images, selected to be histologically diverse on visual inspection, was used by each of the researchers to train Inform to recognize the different phenotypes of interest in each image. Training was run until at least 98% validation accuracy was achieved. The 2 algorithms were compared and visual inspection used to confirm the cell counts. TIL densities for each image were calculated by normalizing validated TIL counts by total area covered by tissue in the image (in units of cells/HPF). Overall TIL densities for each slide were similarly calculated, but using the summation of TIL counts and area across all constituent images. Epithelial and stromal TIL densities employed similar calculations, with counting and area restricted to epithelial/stromal regions identified by tissue segmentation (Inform). Thus, a cell was called epithelial if it fell within epithelial regions identified by Inform, and stromal if it fell within identified stromal regions.
Correlations between TIL densities
Correlations between TIL densities (epithelial and stromal CD8+, CD4+, CD20+, and plasma cell) were quantified with Spearman's correlation coefficient ( Figure S5A) and P values of their significance were adjusted for multiple testing with the Benjamini-Hochberg method. Clustering Hierarchical clustering of TIL density profiles was performed using Ward's method with Euclidean distance. Heatmap values were obtained by normalizing (to a standard Gaussian distribution) across samples for each TIL type. For Figures 1B and 1C , only samples with valid epithelial and stromal TIL densities (i.e., non-zero epithelial and stromal tissue area) are shown. Additionally, for Figure 1B , only samples with both TIL density and Nanostring expression data are shown. The optimal number of clusters (3) was determined with the Dunn index. Malignant clone similarity and TIL subtype To compare whether samples from the same TIL subtype were more clonally similar (within patients), we used a nested ranks test (nestedRanksTest R package), treating patient as a random effect. Specifically, for each pair of samples within a patient, we (1) categorize them as belonging to the same, or different TIL subtypes (til_cluster_comparison); and (2) compute clonal composition similarity as per Clonal architecture distance (clonal_similarity). Then, we run: nestedRanksTest(clonal_similarity $ til_cluster_comparison j patient_id, data)
Nanostring analysis Molecular subtyping Ground truth molecular subtypes for a training set of 62 primary HGSC tumors from Patch et al. (2015) were obtained from the authors. Matched RNA-seq data for these tumors was obtained from the International Cancer Genome Consortium (project OV-AU) and normalized according to section RNA-seq analysis. The resulting expression profiles were pooled with Nanostringderived expression profiles, and subjected to batch effect correction with the ComBAT R package. To confirm the effectiveness of batch correction, expression profiles from all samples were hierarchically clustered. Samples from different batches were not clearly segregated. Following this, a k-nearest neighbors classifier (k = 5) was trained and applied to the data using the Patch et al. (2015) molecular subtypes as ground truth. Six-fold cross-validation accuracy of 85.8% on ground truth data was obtained, similar to that reported in Leong et al. (2015) . As comparison, the diagonal LDA classifier attained an inferior 80.9% cross-validation accuracy and was thus not used. To further test these molecular subtypes, a subset of 62 tumors was additionally profiled with the Affymetrix U133A2 microarray platform. As described in Bashashati et al. (2013) , the expression data from these tumors was normalized with RMA and quantile normalization, corrected for batch effects with ComBAT, pooled with TCGA array expression data (see TCGA foldback inversions), and subjected to another level of batch effect correction with ComBAT. Following the methods of TCGA (Bell et al., 2011) , consensus non-negative matrix factorization (NMF) was applied to determine molecular subtypes (k = 4). NMF-derived subtypes and k-nearest neighbor-derived subtypes were largely concordant (mutual information: 0.74).
Overrepresentation of each molecular subtype or set of molecular subtypes within each IHC-based subgroup (N-TIL, S-TIL, ES-TIL) was computed relative to the other 2 subgroups and other molecular subtypes with Fisher's exact test. Pathway signature analysis Genes were grouped on the basis of pathway annotations from the Nanostring PanCancer Immune Profiling panel (Cesano, 2015) . Metagene expression values were constructed by taking the median of expression values for constituent genes in each pathway.
TCR/BCR-seq analysis Alignment and clonotype calling Alignment to germline TCR and BCR segments was performed with mixcr align from MiXCR 2.0 (Bolotin et al., 2015) , using the human IMGT reference (https://github.com/repseqio/library-imgt/releases, commit d993d704553c0a1e905c702ab93c99c0001b30d9). Reads mapping to the same clonotype were clustered using mixcr assemble, and the resulting TRB and IGH clonotypes were exported with mixcr export. Clonotypes were identified by V and J germline gene names and CDR3 nucleotide sequence. All other mixcr parameters were set to the defaults. Decontamination and quality control Clonotypes with fewer than 5 assigned reads were immediately removed. In order to filter out potential cross-sample contamination, clonotypes shared between samples from different patients were identified. Clonotypes present at an absolute prevalence (read count) in one sample > 25 times lower than in another sample from a different patient were removed (from the former sample). Consistent with contamination, samples (from different patients) arranged close by on each 96-well PCR plate contained a larger number of shared clonotypes. Finally, clonotypes that produced non-functional (frameshift or premature stop) receptor sequences were removed.
Prior to computing repertoire diversity or similarity, TCR/BCR reads were randomly downsampled (using the minimal nonzero library size across the cohort, for TCR/BCR separately) were randomly downsampled (10 times) with replacement from each sample to account for differences in library size. Mean clonotype abundances across these resamplings were used for the computations described below, and the corresponding statistics are reported in Table S2 .
Calculating repertoire diversity
The following indices of diversity were calculated: The Efron-Thisted index estimates the total repertoire diversity (by estimating the number of unseen clonotypes), and the D50 index quantifies the preponderance of rare clonotypes in a repertoire.
Correlations between repertoire diversity and ITH were computed as Spearman's rank correlation, using the first 2 measures listed above. Repertoire similarity analysis Pairwise similarity between TCR/BCR repertoires A and B was calculated with the Morisita-Horn index (R package vegan):
jA j jB j
where A i denotes the number of reads associated with clonotype i in repertoire A, jA j and jB j are the total number of clonotype reads in A and B, respectively, and N is the number of unique clonotypes in AWB. Correlation with clonal composition TCR repertoire and clonal dissimilarity matrices were computed as described above. These dissimilarities were correlated with Mantel's test. Uncorrected P-values are reported in Figure 5 and Figure S3 .
TCR clonotype classification
Previous studies have revealed differences in the physicochemical properties of CDR3 sequences (Li et al., 2016) and VJ (Vb-Jb) gene usage (Emerson et al., 2013 ) between CD8+ and CD4+ T cells. We designed a binary classifier to predict the class (CD8+ or CD4+) of a T cell receptor based on both germline VJ genotype and physicochemical properties of the TCR CDR3 sequence. Training data To train the classifier, unprocessed TCR sequence data from flow-sorted naive CD8+ and CD4+ mononuclear cells derived from 18 unrelated healthy donors were obtained from a previous study (Klarenbeek et al., 2015) . We made an effort to obtain TCR-sequence data of flow sorted CD8+ and CD4+ T cells from other sources as well (Emerson et al., 2013; Li et al., 2016) , but these data were shortread or had been preprocessed (with no raw sequence files available), and thus not amenable to uniform downstream analysis. While these training data were derived from naive T cells, Emerson et al. (2013) have reported that there are no significant differences in Vb and Jb usage between naive and memory T cells (for both CD4+'s and CD8+'s separately). For the analysis described below, we operated under the assumptions that differences in VJ gene usage patterns and CDR3 physicochemical features between CD4+ and CD8+ T cells are similar in the training and multi-site HGSC datasets. We later assessed the validity of these assumptions by comparing predicted CD8/CD4 abundance with results from immunohistochemistry (see Classifier). Alignment and clonotype calling were carried out according to the methods described in Alignment and clonotype calling. Twenty percent of the data, stratified by class, was randomly split off for testing; 5-fold cross-validation was carried out on the remaining 80%. Features V and J genotypes were binarized (80 features). Additionally, Atchley factors (R package HDMD) quantifying the physicochemical properties of amino acids at each position in the CDR3 were used (5n features, where n is the CDR3 amino acid length). Separate classifiers were trained for each length category between 11 and 18 amino acids (0.70 of all clonotypes). The distribution of V and J gene usage was comparable between training and test data. Classifier A binary gradient-boosted tree classifier was trained on the data described in section Alignment and clonotype calling. Training with 5-fold cross-validation was allowed to proceed until 100 consecutive rounds of no improvement in validation accuracy. Based on area under the receiver operating characteristic curve, the gradient-boosted tree classifier outperformed random forest, logistic regression, support vector machine (SVM), and extreme value regression classifiers. The classifier was then applied to clonotype calls from TCR-seq data of multisite HGSC samples to predict whether each clonotype was CD8-type or CD4-type. Clonotypes assigned to either class with >80% probability were kept.
Clonotype distribution broadness across tumor samples within each patient was computed with Simpson's diversity index on the vector of per-sample relative clonotype prevalence values (R package vegan). The significance of differences in the distribution broadness between CD4+ and CD8+ associated TCRs was evaluated by computing the average of CD4+ and CD8+ TCR distribution broadness values within each patient, and applying the Wilcoxon signed-rank test for paired data between the two groups.
Neoantigen analysis HLA typing Four-digit HLA class I types were determined from WGS data for each multisite and background patient (see Neoantigen depletion score) using OptiType (Szolek et al., 2014) . OptiType was run on the WGS bam of the normal sample. Sample-level HLA LOH prediction For OV-AU and Wang et al. (2017) patients, HLA class I loss-of-heterozygosity (LOH) was called from tumor and matched normal bams as well as OptiType 4-digit HLA types using LOHHLA (McGranahan et al., 2017) . HLA LOH was called for an allele if the estimated copy number (with binning and B-allele frequency settings) was < 0.5 and the significance of allelic imbalance p < 0.1 (paired t test, no duplicate counts). A less stringent P-value threshold (compared to McGranahan et al., 2017) where 0 and 1 correspond to the lower and upper bounds of the truncated normal distribution, and the mean and standard deviation p and d were set to be relatively uninformative (0.75 and 0.4, respectively).
MCMC was run for 100,000 iterations, using 50,000 additional tuning iterations. Bin median values were used to anchor total copy number. HLA LOH for a given clone j and allele a was called when R 90% of the posterior trace supported c j,a = 0. Identification of putative neoepitopes All 8 to 11-mer peptides overlapping nonsynonymous SNVs were considered candidate epitopes. MHC-I binding affinity was computed for every mutant and corresponding wild-type allele using netMHCpan-3.0 (Ternette et al., 2016) . Percentile binding scores of % 2%, where the mutant epitope had equal or better affinity than the wild-type epitope, were considered as putative neoepitopes. In cases of HLA LOH, predicted neoepitopes associated with the lost HLA allele were excluded (for subclonal HLA LOH, a neoepitope was only excluded if all clones containing the neoepitope also exhibited loss of the corresponding HLA allele). Neoantigen depletion score Neoepitopes were predicted from nonsynonymous SNVs in a background set of ovarian tumors consisting of 62 primary HGSC tumors from the Australian Ovarian Cancer Study (Patch et al., 2015) and 59 additional HGSC tumors , following the methods described above. Following similar methods to Rooney et al. (2015) , the probability of generating at least one overlapping neoepitope from each trinucleotide pattern was determined.
For each considered tumor sample (from the multi-site HGSC cohort), the expected rate of neoepitope-generating SNVs was calculated from the trinucleotide context of synonymous SNVs and the expected rate of nonsynonymous SNVs per synonymous SNV for each trinucleotide pattern. Mathematically, define N s to be the expected number of nonsynonymous SNVs per synonymous SNV with trinucleotide pattern s and B s to be the expected number of neoepitope-generating SNVs per nonsynonymous SNV with pattern s. Then, for a given sample i, define Y i as the set of synonymous SNVs and N i the set of nonsynonymous SNVs. We can write: where N pred,i and B pred,i are the expected number of nonsynonymous SNVs and neoepitope-generating SNVs in sample i under the null model, respectively. s(m) is the trinucleotide pattern for synonymous SNV m. Denote B obs,i to be the observed number of neoepitope-generating SNVs in i, and N obs;i = jN i j the observed number of nonsynonymous SNVs in i. We then define the neoantigen depletion score as: B obs;i N obs;i B pred;i N pred;i Lower values of this score were interpreted as evidence of higher neoantigen depletion. The within-patient relationship between the response, neoantigen depletion score and the covariate, epithelial CD8+ TIL density was modeled with a Bayesian linear mixed model with patient-specific random intercepts. Samples with fewer than 3 nonsynonymous mutations were excluded. The corresponding R code (using the MCMCglmm R package) was:
MCMCglmm(log(observed_neoantigen_ratio/expected_neoantigen_ratio) $ E_CD8_rescaled, random=$patient_id, data=data, family = ''gaussian'', nitt = 500000, thin = 500, burnin = 50000, prior = prior) where observed_neoantigen_ratio/expected_neoantigen_ratio corresponds to E i , epithelial CD8+ TIL density values were rescaled between 0 and 1, the residual covariance prior was set to be relatively uninformative (V = 1 and nu = 0.002 in R), and likewise for the random effect prior (V = 1, nu = 1, alpha.mu = 0, alpha.V = 1000 in R). For the fixed effect coefficient, an uninformative prior with mean 0 and variance 10 10 was used. Lack of autocorrelation in the MCMC traces was confirmed with autocorr from the coda R package.
Posterior densities of parameter estimates were checked to ensure certain assumptions of the model (e.g., fixed effect being Gaussian-distributed) were met. Reported significance values correspond to area under the (right) tail of the posterior distribution of the fixed effect coefficient. The across-patient relationship was computed similarly, but with no patient-specific intercept term. To compute subclonal-or clonal-specific correlations, observed nonsynonymous mutations (and transitively, neoepitopes) were classified based on the clonal phylogenies inferred in Clonal phylogenies & postprocessing. Similar correlations between subclonal neoantigen depletion and epithelial CD8+ TIL densities were observed using multilevel analysis (intrapatient Spearman's correlation p = 0.034 across the cohort and p = 6.1 3 10 À5 in patients containing samples with highest epithelial CD8+ TIL densities; all between-patient p > 0.2).
Lymphocyte marker expression and HLA LOH CD3D, CD8A, and CD8B expression values was extracted from Nanostring expression data for HGSC cases from and RNA-seq expression data from OV-AU cases (see RNA-seq analysis). As expression data from few genes was available from the Supplemental Figures 
